Press Releases
Media Contact:
Lorie Calvo
425-608-3008
Northwest Biotherapeutics to Present at the CE Unterberg, Towbin Emerging Growth Conference
Personalized Brain Cancer Vaccine Data to be Updated
BOTHELL, WA– July 10, 2006 – Northwest Biotherapeutics (OTCBB: NWBT.OB) announced today that Alton Boynton, Ph.D. company President will present an update on the Company’s late stage clinical trials for brain and prostate cancer, recent FDA clearances of two additional INDs for multiple additional cancers (including lung cancer), and ongoing long-term survival data from the Company’s prior early stage clinical trials. The presentation will take place July 11 at 3:56 PM Eastern Time at the CE Unterberg, Towbin Emerging Growth Conference. The conference is being held at the Mandarin Oriental Hotel in New York City.
The presentation will be webcast live and available for replay for 90 days from the Northwest Biotherapeutics website, www.nwbio.com under the "Investor and Media" section.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company's three lead product candidates are:
DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial recently cleared by the FDA; DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial recently cleared by the FDA; and monoclonal antibodies to CXCR4 which are in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this press release that are not historical facts are forward-looking statements including, without limitation, the statements regarding completion of the private placement and the anticipated gross proceeds of the private placement and the uses thereof. These forward-looking statements are subject to risks and uncertainties that could cause actual events to differ materially from those stated including, among others, risks related to the satisfaction or waiver of the conditions to closing the private placement and the risk that the private placement may not be consummated, as well as those risks and uncertainties disclosed from time to time in reports filed by the Company with the U.S. Securities and Exchange Commission. Additional information on factors, which could affect the Company’s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
|
